Wang et al demonstrated on prostate cancer cell line that inhibition of mTORC1 and AR pathways by a combination of rapamycin and bicatulamide led to apoptosis and could be a therapeutic value in prostate cancer treatment [41]. The gene discussed is AR; the disease is prostate cancer.